학술논문
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandResearch in context
Document Type
article
Author
Paul Thoueille; Susana Alves Saldanha; Fabian Schaller; Eva Choong; Aline Munting; Matthias Cavassini; Dominique Braun; Huldrych F. Günthard; Katharina Kusejko; Bernard Surial; Hansjakob Furrer; Andri Rauch; Mathieu Rougemont; Pilar Ustero; Alexandra Calmy; Marcel Stöckle; Catia Marzolini; Caroline Di Benedetto; Enos Bernasconi; Patrick Schmid; Rein Jan Piso; Pascal Andre; François R. Girardin; Monia Guidi; Thierry Buclin; Laurent A. Decosterd
Source
The Lancet Regional Health. Europe, Vol 36, Iss , Pp 100793- (2024)
Subject
Language
English
ISSN
2666-7762
Abstract
Summary: Background: The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic failure. This study aims to verify whether drug concentrations measured in a real-world setting are consistent with those previously reported. Methods: SHCS-879 is a nationwide observational study within the Swiss HIV Cohort Study for the monitoring of people with HIV (PWH) on long-acting cabotegravir plus rilpivirine. Samples were collected from March 2022 to March 2023. Findings: Overall, 725 samples were obtained from 186 PWH. Our data show a large inter-individual variability in cabotegravir and rilpivirine concentrations, with some individuals exhibiting repeatedly low concentrations. Rilpivirine trough concentrations were consistent with those from Phase III trials, while cabotegravir concentrations were lower. The first concentrations quartile was only slightly above the target of 664 ng/mL. Exploratory statistical analyses found 35% (p